Competent authority

A competent authority is a national or supranational government agency legally authorized to regulate medicinal products. In the European Union, the term refers to the National Competent Authorities (NCAs) of individual member states, which authorize medicines and grant marketing authorizations. In the United States, the Food and Drug Administration (FDA) fills this role, often called a regulatory authority or agency.

A competent authority regulates the process behind testing data

A competent authority regulates the process that produces testing data rather than generating the data itself. It sets scientific guidelines, inspects manufacturers for compliance with Good Manufacturing Practice (GMP), and issues GMP certificates. While it oversees clinical trial laboratories, it does not directly measure the purity, identity, or safety of a sample.

This distinction matters when you evaluate a lab report. A GMP certificate confirms that a manufacturer's quality system passed inspection, but it does not certify the purity of a specific batch. Analytical data on a Certificate of Analysis (CoA) comes from the testing laboratory, which is separate from the competent authority.

A competent authority is distinct from related roles and certifications

• A competent authority is not the testing laboratory that generates CoA data.
• A competent authority is not an accreditation body, such as ISO 17025 assessors, which evaluate technical competence rather than enforce statutory regulation.
• In the EU, the EMA acts as a coordinating agency, while the National Competent Authorities (NCAs) grant the actual authorizations.
• A competent authority is distinct from CLIA certification, a specific US clinical laboratory program.

Sources

1. National competent authorities (human) | European Medicines Agency (EMA)
2. FDA vs. EMA: Key Differences in US & EU Drug Regulation | IntuitionLabs
3. Accreditation of Medical Laboratories – System, Process, Benefits for Labs - PMC
4. EMA Flexibilities, Authorities, and Mechanisms - Regulatory Processes for Rare Disease Drugs in the United States and European Union - NCBI Bookshelf
5. FDA vs EMA: Key Regulatory Differences for Pharmaceuticals - LS Academy
6. Requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials - Scientific guideline | European Medicines Agency (EMA)
7. Abbreviations in Committee CMD documents and in relation to ...
8. Requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials - Rev. 2
9. QP declaration guidance and template adopted by CMDh, CMDv, CHMP and CVMP (with CVMP editorial amendments) March 2014
10. The Challenges for EU User Testing Policies for Patient Information Leaflets
11. Global Pharmaceutical Regulation: Comparative Frameworks ... - PMC
12. The regulatory landscape of laboratory developed tests: Past, present, and a perspective on the future
13. Clinical Laboratory Improvement Amendments (CLIA) | FDA
14. Conduct of inspections of pharmaceutical manufacturers or importers
15. Reflection paper on laboratories that perform the analysis or evaluation of clinical trial samples dated 05 Dec 2011
16. FDA and EMA inspections: Similarities and Differences | Scilife
17. FDA Sets Peptide Impurity Thresholds as Low as 0.10%, Oath ...
18. Development and manufacture of synthetic peptides - Scientific guideline | European Medicines Agency (EMA)